Literature DB >> 19554553

Overexpression of nucleolin in engrafted acute myelogenous leukemia cells.

Sebastiano Gattoni-Celli, Carl L Buckner, John Lazarchick, Robert K Stuart, Daniel J Fernandes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19554553     DOI： 10.1002/ajh.21461

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

1.  An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Authors:  L Angenendt; S Reuter; D Kentrup; A S Benk; F Neumann; J Hüve; A C Martens; C Schwöppe; T Kessler; L H Schmidt; T Sauer; C Brand; J-H Mikesch; G Lenz; R M Mesters; C Müller-Tidow; W Hartmann; E Wardelmann; D Neri; W E Berdel; C Roesli; C Schliemann
Journal:  Leukemia       Date:  2017-06-30       Impact factor: 11.528

2.  Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization.

Authors:  Ara G Hovanessian; Calaiselvy Soundaramourty; Diala El Khoury; Isabelle Nondier; Josette Svab; Bernard Krust
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

3.  Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.

Authors:  Ka-To Shum; Jiehua Zhou; John J Rossi
Journal:  J Cancer Ther       Date:  2013-06-01

4.  Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.

Authors:  Virginie Marcel; Frédéric Catez; Caroline M Berger; Emeline Perrial; Adriana Plesa; Xavier Thomas; Eve Mattei; Sandrine Hayette; Pierre Saintigny; Philippe Bouvet; Jean-Jacques Diaz; Charles Dumontet
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

Review 5.  Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases.

Authors:  Maher M Aljohani; Dana Cialla-May; Jürgen Popp; Raja Chinnappan; Khaled Al-Kattan; Mohammed Zourob
Journal:  Molecules       Date:  2022-01-07       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.